Global Patent Index - EP 3578185 A1

EP 3578185 A1 20191211 - PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION

Title (en)

PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION

Title (de)

PROTONENBINDENDE POLYMERE ZUR ORALEN VERABREICHUNG

Title (fr)

POLYMÈRES LIANT LES PROTONS POUR ADMINISTRATION ORALE

Publication

EP 3578185 A1 20191211 (EN)

Application

EP 19169259 A 20140605

Priority

  • US 201361831445 P 20130605
  • EP 17177221 A 20140605
  • EP 14742001 A 20140605
  • US 2014041152 W 20140605

Abstract (en)

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

IPC 8 full level

A61K 31/785 (2006.01); A61P 3/12 (2006.01)

CPC (source: EP IL KR MX RU US)

A61K 31/785 (2013.01 - EP IL KR MX RU US); A61P 3/12 (2018.01 - EP IL KR US); C08F 226/02 (2013.01 - EP IL MX US); C08G 73/02 (2013.01 - EP IL MX US); C08G 73/024 (2013.01 - EP IL MX US); G01N 1/4077 (2013.01 - US); C08F 226/02 (2013.01 - KR); C08G 73/02 (2013.01 - KR); C08G 73/024 (2013.01 - KR); G01N 2001/4083 (2013.01 - US); G01N 2001/4088 (2013.01 - US); Y10T 428/2982 (2015.01 - EP MX US)

Citation (applicant)

  • US 7459502 B2 20081202 - CONNOR ERIC [US], et al
  • "Am. J. Kidney Dis.", vol. 35, 2000, NATIONAL KIDNEY FOUNDATION, pages: 1 - 140
  • RAPHAEL, KL; ZHANG, Y; WEI, G ET AL.: "Serum bicarbonate and mortality in adults in NHANES", NEPHROL. DIAL. TRANSPLANT, vol. 28, 2013, pages 1207 - 1213
  • LEMAN, J; LITZOW, JR; LENNON, EJ: "The effects of chronic acid loads in normal man: further evidence for the participation of bone mineral in the defense against chronic metabolic acidosis", J. CLIN. INVEST., vol. 45, 1966, pages 1608 - 1614
  • FRANCH HA; MITCH WE: "Catabolism in uremia: the impact of metabolic acidosis", J. AM. SOC. NEPHROL., vol. 9, 1998, pages 78 - 81
  • BALLMER, PE; MCNURLAN, MA; HULTER, HN ET AL.: "Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans", J. CLIN. INVEST., vol. 95, 1995, pages 39 - 45
  • FARWELL, WR; TAYLOR, EN: "Serum anion gap, bicarbonate and biomarkers of inflammation in healthy individuals in a national survey", CMAJ, vol. 182, 2010, pages 137 - 141
  • KDOQI BONE GUIDELINES: AMERICAN JOURNAL OF KIDNEY DISEASES, vol. 42, 2003, pages S1 - S201
  • WIDMER B; GERHARDT RE; HARRINGTON JT; COHEN JJ: "Serum electrolyte and acid base composition: The influence of graded degrees of chronic renal failure", ARCH INTERN MED, vol. 139, 1979, pages 1099 - 1102
  • DOBRE M; YANG, W; CHEN J: "Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the chronic renal insufficiency cohort (CRIC) study", AM. J. KIDNEY DIS., vol. 62, 2013, pages 670 - 678
  • YAQOOB, MM: "Acidosis and progression of chronic kidney disease", CURR. OPIN. NEPHROL. HYPERTENS., vol. 19, 2010, pages 489 - 492
  • ADROGUE HJ; MADIAS NE: "Comprehensive Clinical Nephrology", 2003, CV MOSBY, article "Respiratory acidosis, respiratory alkalosis, and mixed disorders", pages: 167 - 182
  • DUBOSE TD; MACDONALD GA: "Acid-base and electrolyte disorders: A companion to Brenners and Rectors the Kidney", 2002, WB SAUNDERS, article "renal tubular acidosis", pages: 189 - 206
  • GOLDBERG M: "Primer on Kidney Diseases", 2005, NATIONAL KIDNEY FOUNDATION, PHILADELPHIA, ELSEVIER-SAUNDERS, article "Approach to Acid-Base Disorders", pages: 104 - 109
  • SZERLIP HM: "Primer on Kidney Diseases", 2005, NATIONAL KIDNEY FOUNDATION, PHILADELPHIA, ELSEVIER-SAUNDERS, article "Metabolic Acidosis", pages: 74 - 89
  • "Am. J. Kidney Dis.", vol. 35, 2000, NATIONAL KIDNEY FOUNDATION, pages: 51 - 140
  • YAQOOB, MM.: "Acidosis and progression of chronic kidney disease", CURR. OPIN. NEPHROL. HYPERTEN., vol. 19, 2010, pages 489 - 492
  • MITCH WE: "Influence of metabolic acidosis on nutrition", AM. J. KIDNEY DIS., vol. 29, 1997, pages 46 - 48
  • DE BRITO-ASHURST !; VARAGUNAM M; RAFTERY MJ ET AL.: "Bicarbonate supplementation slows progression of CKD and improves nutritional status", J. AM. SOC. NEPHROL., vol. 20, 2009, pages 2075 - 2084
  • LEMANN J JR; BUSHINSKY DA; HAMM LL: "Bone buffering of acid and base in humans", AM. J. PHYSIOL RENAL PHYSIOL., vol. 285, no. 5, November 2003 (2003-11-01), pages F811 - 32
  • LINDENFELD, J CARDIAC FAILURE, vol. 16, no. 6, 2010, pages 475
  • BREZINA, 2004 KIDNEY INT., vol. 66, no. S90, 2004, pages S39 - S45
  • FAN, 2009 NEPHROL DIAL TRANSPLANT, vol. 24, 2009, pages 3794
  • WRONG, 0 ET AL., CLINICAL SCIENCE, vol. 28, 1965, pages 357 - 375
  • STEVENS T; CONWELL DL; ZUCCARO G; VAN LENTE F; KHANDWALA F; PURICH E ET AL.: "Electrolyte composition of endoscopically collected duodenal drainage fluid after synthetic porcine secretin stimulation in healthy subjects", GASTROINTESTINAL ENDOSCOPY, vol. 60, no. 3, 2004, pages 351 - 5, XP004855304, DOI: doi:10.1016/S0016-5107(04)01809-7
  • FORDTRAN J; LOCKLEAR T: "Ionic constituents and osmolality of gastric and small-intestinal fluids after eating", DIGEST DIS SCI., vol. 11, no. 7, 1966, pages 503 - 21
  • PHISITKUL S; HACKER C; SIMONI J; TRAN RM; WESSON DE: "Dietary protein causes a decline in the glomerular filtration rate of the remnant kidney mediated by metabolic acidosis and endothelin receptors", KIDNEY INTERNATIONAL, vol. 73, no. 2, 2008, pages 192 - 9
  • STEED, JW: "Supramolecular Chemistry", 2009, JOHN WILEY AND SONS, pages: 226
  • KIELLAND, J, J. AM. CHEM. SOC., vol. 59, 1937, pages 1675 - 1678
  • "Remington's Pharmaceutical Sciences"

Citation (search report)

  • [A] WO 2005041902 A2 20050512 - ILYPSA INC [US], et al
  • [A] US 2002159968 A1 20021031 - PETERSEN JOHN S [US], et al
  • [A] WO 2008027551 A2 20080306 - GENZYME CORP [US], et al
  • [A] WO 2008103368 A1 20080828 - GENZYME CORP [US], et al
  • [A] WO 2008011047 A2 20080124 - GENZYME CORP [US], et al
  • [A] US 2010189679 A1 20100729 - INOUE ATSUSHI [JP], et al
  • [A] S. D. NAVANEETHAN ET AL: "Serum Bicarbonate and Mortality in Stage 3 and Stage 4 Chronic Kidney Disease", CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 6, no. 10, 1 October 2011 (2011-10-01), pages 2395 - 2402, XP055330171, ISSN: 1555-9041, DOI: 10.2215/CJN.03730411
  • [A] BARTON BREZINA ET AL: "Acid loading during treatment with sevelamer hydrochloride: Mechanisms and clinical implications", KIDNEY INTERNATIONAL, vol. 66, no. 90, 1 September 2004 (2004-09-01), LONDON, GB, pages S39 - S45, XP055523207, ISSN: 0085-2538, DOI: 10.1111/j.1523-1755.2004.09007.x
  • [T] WESSON DONALD E ET AL: "Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension", LANCET, ELSEVIER, AMSTERDAM, NL, vol. 394, no. 10196, 24 June 2019 (2019-06-24), pages 396 - 406, XP085797718, ISSN: 0140-6736, [retrieved on 20190624], DOI: 10.1016/S0140-6736(19)31388-1
  • [T] DAVID A. BUSHINSKY ET AL: "Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD", CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 13, no. 1, 4 November 2017 (2017-11-04), pages 26 - 35, XP055625921, ISSN: 1555-9041, DOI: 10.2215/CJN.07300717

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2014197725 A1 20141211; AU 2014274817 A1 20151224; AU 2014274817 B2 20190523; AU 2019219800 B1 20190919; AU 2019275584 A1 20200102; AU 2019275584 B2 20211021; BR 112015030142 A2 20170725; BR 112015030142 B1 20230307; CA 2912911 A1 20141211; CA 2912911 C 20231003; CN 105377270 A 20160302; CN 105377270 B 20200904; CN 111671766 A 20200918; CN 111671766 B 20240308; CN 111671767 A 20200918; CN 111671767 B 20240308; CY 1119611 T1 20180404; CY 1121801 T1 20200731; CY 1123673 T1 20220324; DK 3003327 T3 20171023; DK 3287133 T3 20190701; DK 3578185 T3 20201102; EP 3003327 A1 20160413; EP 3003327 B1 20170809; EP 3287133 A1 20180228; EP 3287133 B1 20190417; EP 3578185 A1 20191211; EP 3578185 B1 20200805; EP 3812761 A1 20210428; ES 2646271 T3 20171213; ES 2733493 T3 20191129; ES 2834485 T3 20210617; HK 1222120 A1 20170623; HK 1223288 A1 20170728; HK 1251151 B 20200424; HR P20171590 T1 20171229; HR P20191074 T1 20190920; HR P20201767 T1 20201225; HU E034836 T2 20180328; HU E043999 T2 20190930; HU E051198 T2 20210301; IL 242758 B 20200130; IL 271932 A 20200227; IL 271932 B 20201130; IL 278183 A 20201130; IL 278183 B 20210930; JP 2016520652 A 20160714; JP 2019065024 A 20190425; JP 2020203917 A 20201224; JP 2022107004 A 20220720; JP 6453860 B2 20190116; JP 6759316 B2 20200923; JP 7075455 B2 20220525; KR 102318910 B1 20211029; KR 102633597 B1 20240206; KR 20160041855 A 20160418; KR 20210131457 A 20211102; KR 20230114326 A 20230801; KR 20240023672 A 20240222; LT 3003327 T 20171227; LT 3287133 T 20190710; LT 3578185 T 20201125; MX 2015016527 A 20160722; MX 2019005300 A 20190812; MX 2021013880 A 20220602; MX 364785 B 20190507; NO 2905572 T3 20171216; PL 3003327 T3 20180228; PL 3287133 T3 20191031; PT 3003327 T 20171109; PT 3287133 T 20190712; PT 3578185 T 20201110; RS 59033 B1 20190830; RS 61005 B1 20201130; RU 2015155596 A 20170718; RU 2015155596 A3 20180510; RU 2728778 C2 20200731; SI 3003327 T1 20180131; SI 3287133 T1 20190930; SI 3578185 T1 20210129; TR 201909355 T4 20190722; US 10363268 B2 20190730; US 10369169 B1 20190806; US 10391118 B2 20190827; US 11197887 B2 20211214; US 2015056451 A1 20150226; US 2016074430 A1 20160317; US 2018015121 A1 20180118; US 2018280428 A1 20181004; US 2019134075 A1 20190509; US 2019231812 A1 20190801; US 2020206260 A1 20200702; US 2022096534 A1 20220331; US 9205107 B2 20151208; US 9925214 B2 20180327; US 9993500 B2 20180612

DOCDB simple family (application)

US 2014041152 W 20140605; AU 2014274817 A 20140605; AU 2019219800 A 20190822; AU 2019275584 A 20191204; BR 112015030142 A 20140605; CA 2912911 A 20140605; CN 201480032395 A 20140605; CN 202010780603 A 20140605; CN 202010780604 A 20140605; CY 171101159 T 20171106; CY 191100694 T 20190704; CY 201101028 T 20201030; DK 14742001 T 20140605; DK 17177221 T 20140605; DK 19169259 T 20140605; EP 14742001 A 20140605; EP 17177221 A 20140605; EP 19169259 A 20140605; EP 20183421 A 20140605; ES 14742001 T 20140605; ES 17177221 T 20140605; ES 19169259 T 20140605; HK 16110308 A 20160830; HK 16111588 A 20161005; HK 18110550 A 20180816; HR P20171590 T 20171018; HR P20191074 T 20190614; HR P20201767 T 20201102; HU E14742001 A 20140605; HU E17177221 A 20140605; HU E19169259 A 20140605; IL 24275815 A 20151124; IL 27193220 A 20200109; IL 27818320 A 20201020; JP 2016518006 A 20140605; JP 2018233254 A 20181213; JP 2020147224 A 20200902; JP 2022079329 A 20220513; KR 20157036999 A 20140605; KR 20217034420 A 20140605; KR 20237024806 A 20140605; KR 20247003745 A 20140605; LT 14742001 T 20140605; LT 17177221 T 20140605; LT 19169259 T 20140605; MX 2015016527 A 20140605; MX 2019005300 A 20151201; MX 2021013880 A 20151201; NO 15000230 A 20150127; PL 14742001 T 20140605; PL 17177221 T 20140605; PT 14742001 T 20140605; PT 17177221 T 20140605; PT 19169259 T 20140605; RS P20190806 A 20140605; RS P20201307 A 20140605; RU 2015155596 A 20140605; SI 201430466 T 20140605; SI 201431241 T 20140605; SI 201431698 T 20140605; TR 201909355 T 20140605; US 201414311852 A 20140623; US 201514944844 A 20151118; US 201715715934 A 20170926; US 201816002269 A 20180607; US 201816002306 A 20180607; US 201916375843 A 20190404; US 201916542969 A 20190816; US 202117546339 A 20211209